Biolegend, 343303, FITC anti-human HLA-A2 Antibody, 25tests

HLA-A2 is most common in Northern Asia and North America populations. MHC class I antigens associated with β2-microglobulin are expressed by all human nucleated cells. MHC class I molecules are involved in presentation of antigens to CD8 + T cells, playing an important role in cell-mediated immune responses and tumor surveillance.
25tests
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Papain solubilized HLA-A2
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation: The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser: Blue Laser (488 nm)
Application Notes: The BB7.2 antibody recognizes human leukocyte antigen (HLA) A2 which is a subset of MHC-class I molecules encoded by A*02 alleles. Additional reported applications (for the relevant formats) include: immunoprecipitation3.
Application References(PubMed link indicates BioLegend citation): Brodsky FM, et al. 1979. Immunol. Rev. 47:3. Parham P and Brodsky FM. et al. 1981. Hum. Immunol. 3:277. Lubben NB, et al. 2007. Mol Biol Cell. 18:3351. (IP)
Product Citations: Lao L, et al. 2023. Cancer Immunol Res. 11:320. PubMed Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed Xiao C, et al. 2023. Nat Aging. 3:418. PubMed Zhang H, et al. 2021. Front Immunol. 12:644520. PubMed Kim HS, et al. 2023. Bioact Mater. 21:241. PubMed Ding L, et al. 2023. J Clin Invest. 133: . PubMed Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed Xiao C, et al. 2022. iScience. 25:103934. PubMed Dean L, et al. 2015. Forensic Sci Int. 17: 8-16. PubMed Wu W, et al. 2020. Oncol Lett. 0.91875. PubMed Kerstein A, et al. 2016. J Autoimmun. S0896-8411(16)30186-X. PubMed Qiu C, et al. 2022. Front Immunol. 12:764949. PubMed Su S, et al. 2017. Cell Res. 10.1038/cr.2017.34. PubMed Williamson LM, et al. 2021. NPJ Precis Oncol. 5:103. PubMed Huygens C, et al. 2015. J Biol Chem. 290: 20105-20116. PubMed Meng J, et al. 2010. Clin Vaccine Immunol. 1.325694444. PubMed Morvan MG, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed Deng J, et al. 2021. J Leukoc Biol. 110:1171. PubMed Pan X, et al. 2021. Front Pharmacol. 11:539261. PubMed
RRID: AB_1659246 (BioLegend Cat. No. 343303) AB_1659245 (BioLegend Cat. No. 343304)
Structure: Ig superfamily
Distribution: A*02 individuals leukocytes
Function: Antigen presentation
Ligand/Receptor: CD8, CD3/TCR
Cell Type: Leukocytes
Biology Area: Immunology
Molecular Family: MHC Antigens
Gene ID: 3105
UniProt: View information about HLA-A2 on UniProt.org
Clone: BB7.2
Regulatory Status: RUO
Other Names: MHC-class I
Isotype: Mouse IgG2b, κ